Cannabidiol for epilepsy

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Also followed for narrower conditions: Drug Resistant Epilepsy, Epilepsies, Myoclonic, Epilepsy, Absence, Lennox Gastaut Syndrome, Spasms, Infantile

Why this status

  1. 26 May 2016: Trial registered, NCT02783092
  2. 9 Jan 2019: Trial started, NCT02783092

The trials

NCT02695537: University of Alabama at Birmingham (UAB) Pediatric CBD Program

State
Completed
Phase
Phase 1
People
89 taking part
Started
Apr 2015
Primary completion
27 Feb 2019
Arms
Epidiolex 100 milligram/milliliter (mg/mL) oral solution
Results
Posted on the registry
Papers
doi:10.1016/j.yebeh.2019.03.042, doi:10.1080/13554794.2017.1391294
  1. 1 Mar 2016: Trial registered
  2. 27 Feb 2019: Trial completed
  3. 10 Apr 2020: Trial results posted

NCT02700412: University of Alabama at Birmingham (UAB) Adult CBD Program

State
Completed
Phase
Phase 1
People
80 taking part
Started
Apr 2015
Primary completion
8 Aug 2019
Arms
Epidiolex 100 milligram/milliliter (mg/mL) oral solution
Results
Posted on the registry
Papers
doi:10.1016/j.yebeh.2019.03.042, doi:10.1080/13554794.2017.1391294
  1. 7 Mar 2016: Trial registered
  2. 8 Aug 2019: Trial completed
  3. 8 May 2020: Trial results posted

NCT02783092: A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy

State
State not given
Phase
Phase 3
People
126 planned
Started
9 Jan 2019
Primary completion
10 Jul 2024
Arms
Cannabidiol
Results
None posted
  1. 26 May 2016: Trial registered
  2. 9 Jan 2019: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Cardiolrx, Canapure PH, Cannabidiol (Epidiolex), Cannabidiol Oral Solution, Epidiolex, Epidiolex 100 mg/mL Oral Solution, Epidyolex, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose, GWP42003-P 5 mg/kg/day Dose, MediCabilis.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.